CytomX Therapeutics, Inc. (CTMX) NASDAQ
3.21
-0.0084(-0.26%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
3.21
-0.0084(-0.26%)
Currency In USD
| Previous Close | 3.22 |
| Open | 3.23 |
| Day High | 3.3 |
| Day Low | 3.2 |
| 52-Week High | 8.21 |
| 52-Week Low | 1.72 |
| Volume | 761,169.73 |
| Average Volume | 6.87M |
| Market Cap | 516.5M |
| PE | -6.18 |
| EPS | -0.52 |
| Moving Average 50 Days | 4.13 |
| Moving Average 200 Days | 4.01 |
| Change | -0.01 |
CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026
GlobeNewswire Inc.
Mar 04, 2026 1:00 PM GMT
SOUTH SAN FRANCISCO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report full year 2025 financial results on Mo
CytomX Therapeutics to Present at Upcoming February Conferences
GlobeNewswire Inc.
Feb 04, 2026 1:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following conferenc
CytomX Therapeutics Announces Business Update and Company Milestones for 2026
GlobeNewswire Inc.
Jan 08, 2026 1:00 PM GMT
- CX-2051 (varsetatug masetecan) Phase 1 Colorectal Cancer expansion data on track for Q1 2026 - - Varsetatug masetecan (“Varseta-M”) Phase 1 combination study with bevacizumab in Colorectal Cancer to start in Q1 2026 with initial data expected by 1H